Member Info for tecbadger

Malachi parsotix could expand the offering of illumina/grail. You are correct that they are focused on cfDNA right now to look for cancer biomarkers however even the power of NGS can struggle with the scarcity of cfDNA

If they used parotix to harvest CTCs and then ran nucleic acid extraction they could analyse high quality DNA and also RNA ( there are lots of biomarkers that are caused by fusion variants which are only detectable in RNA)

As far as I'm aware illumina technologies don't cover the nucleic acid extraction they use partner's so Parsotix could I my expand the use cases of tech like grail for them and take nothing away.

My dad would batter your dad

I work in medical devices and can tell you its currently a nightmare to hit deliverables that involve either healthcare or regulatory body third party input.

The other parties are swamped and commitments made on best knowledge a few months ago go out of the window when something like Omicron hits.

I'm very excited by Parsotix, I've read several market reports that predict liquid biopsy testing will explode throughout the 2020s and you get better quality DNA and csn only get RNA from circulating tumour cells compared to circulating free DNA. This company could go places fast

On track record ODX probably have the approval but forgot to RNS it

The Chinese tests may well detect Omicron but they have to do the study to prove it which requires real clinical samples. We will likely see more and more announcements now as there isn't such a limited supply of Omicron true positives.

Those who have been here two years know this will be a meh open.

Nice and as expected since our test targets the N protein which only has 2 genetic variants (compared with over 30 on the s protein)

Thanks for sharing

ODX is like my dear old dad.

Both struggle with any sort of regulations and can no longer get a rise.

To be fair Altona are a very established player in IVD

Oh look. Kevin the crank is back yay

This is the final indicator as to what the UK really thinks about its small cap diagnostic companies. Disgusting given the funds invested in badly investigated products.

The chances of the ODX test not detecting Omicron are low. The test detects the nucleocapsid protein which only has 1 unique base change in its structure when compared to the Alpha variant which means the protein structure is highly unlikely to be changed enough to prevent the antibody binding within the device.

I'd be more concerned about avacta which targets the S protein and has 30 plus mutations in Omicron (which makes sense for the S protein as its the viruses entry into cells through binding the ACE2 receptor)

That is going ticket an absolute nightmare to organise

It's like none if you have seen punit before

You can still self cert new in vitro diagnostic medical devices until 26may2022 which is the date that the tougher CE-IVD regulations are due to start.

The EU is currently discussing a delay to the regulation implementation as both manufacturers and healthcare institutions are not ready for the tougher processes (partly due to the pandemic)

Long story short as long as a new device is self cert and placed before 26may2022 there will likely be a runway of a few years before it needs to be reassessed under the new regulation.

The likely barrier here is actually medical credibility which can onky be built up over time as customers purchase and successfully use the device. You also have to consider that at this point in the pandemic a potential customer will have to make an active choice to change what test they are using which requires complex process change. They may also be contractually bound to a different solution.

I mean I could see this getting back to poundland but there will be a tide of selling on the way there as LTH get out

Spike is bonkers no way in hell I'm buying in on this. Look st what happened with GDR recently

I thought this board was bad when it was just the Eeyore crew. This new ADHD gang is actually worse.

No signs of intelligent life anywhere

I would expect the company to be in discussions to acquire Omicron variant samples to assess performance of the mologic LFT.

In my opinion the risk of Omicron not being detected by mologic as the test targets the nucleocapsid protein.

Most of Omicrons mutations versus baseline are on the spike protein only 4 of them are on the nucleocapsid and 3 of those 4 are common with the lambda variant.

A single unique variant is unlikely to adjust the protein structure of the nucleocapsid enough to prevent binding in the test process. Hopefully we will see an RNS on this within a month or so.

Fingers crossed for UK approval to begin selling through DAM.

Novicehunter you schlaaaaaaaaaaag